SCHEDULE: T. Rowe Price Discloses 5.4% Stake in Oric Pharmaceuticals

T. Rowe Price Associates, Inc. has reported a beneficial ownership of 5.4% in Oric Pharmaceuticals Inc., holding over 5.3 million shares.

Summary

• T. Rowe Price Associates, Inc. has filed a Schedule 13G, indicating it beneficially owns 5,387,783 shares of Oric Pharmaceuticals Inc. common stock.
• This holding represents 5.4% of the class of securities.
• The filing specifies sole voting power for 5,382,293 shares and sole dispositive power for 5,387,783 shares.
• The filing date is March 31, 2026, with the certification signed on May 15, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates a major institutional investor has taken a significant passive stake, suggesting confidence in the company's underlying value, but without any indication of active support or strategic involvement.

Positives

• T. Rowe Price Associates, Inc., a significant institutional investor, has taken a notable stake in Oric Pharmaceuticals Inc., suggesting confidence in the company's prospects.
• The ownership of over 5.3 million shares and 5.4% of the class indicates substantial investment.

Negatives

• The filing is a Schedule 13G, which is an informational filing for passive investors, and does not indicate any intent to influence or control the issuer. T. Rowe Price expressly denies beneficial ownership for the purpose of control.

Risks

• As a Schedule 13G filing, it indicates a passive investment, meaning T. Rowe Price is not actively seeking to influence the company's control or operations. This could imply a lack of strategic partnership or active support beyond investment.
• The filing does not provide details on the specific investment strategy or rationale behind acquiring this stake, leaving the long-term intentions open to interpretation.

Future Outlook

This filing is a Schedule 13G, which reports passive ownership and does not contain forward-looking statements or guidance from Oric Pharmaceuticals Inc. or T. Rowe Price Associates, Inc. regarding future performance or strategy.

Management Comments

• T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that the acquisition of a significant passive stake by a major asset manager like T. Rowe Price Associates, Inc. in a biotechnology or pharmaceutical company like Oric Pharmaceuticals Inc. often signals a positive view on the company's research and development pipeline or market potential, even without direct involvement in management.

Stakeholder Impact

• Shareholders may view the increased institutional ownership positively, potentially leading to increased liquidity and market interest in Oric Pharmaceuticals Inc. stock.
• The passive nature of the investment means no direct impact on Oric Pharmaceuticals Inc.'s operational control or strategic direction from T. Rowe Price Associates, Inc.

Next Steps

• T. Rowe Price Associates, Inc. will continue to hold its shares in Oric Pharmaceuticals Inc. as a passive investment.
• Oric Pharmaceuticals Inc. will continue its operations and strategic initiatives as planned.

Key Dates

Recommendation

The filing indicates a significant passive investment by a major institutional investor, which is generally a positive signal. However, without further information on Oric Pharmaceuticals Inc.'s performance or strategic plans, and given the passive nature of the investment, a 'hold' recommendation is appropriate for seasoned investors, suggesting maintaining current positions while awaiting more substantive company updates.

Keywords

Oric Pharmaceuticals, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment